3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Radiotherapy
8
camrelizumab
3
Drug Therapy
3
Cisplatin
3
sintilimab
2
Paclitaxel
2
Neoadjuvant Therapy
2
toripalimab
1
tislelizumab
1
pembrolizumab
1
durvalumab
1
anlotinib
1
Surgical Procedures, Operative
1
Radiofrequency Ablation
1
Radiation
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Observation
1
Narrow Band Imaging
1
Magnetic Resonance Spectroscopy
1
Laparoscopy
1
Immune Checkpoint Inhibitors
1
Gene Expression Profiling
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Esophagectomy
1
Endoscopy, Digestive System
1
Docetaxel
1
Consolidation Chemotherapy
1
Chemoradiotherapy
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Esophageal Squamous Cell Carcinoma
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled